Loading stock data…
$2.54+0.06 (+2.21%)
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.
Entera Bio Ltd. in the Healthcare sector is trading at $2.54 with a market capitalization of $442M. Wall Street consensus targets $9.75 (4 analysts), implying a +283.1% move over the next 12 months. The stock is currently 39% below its 52-week high of $4.20, remaining 39.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$4.56M↓ | -$3.54M↓ | -$3.04M↑ | -$3.26M↓ | -$2.67M |
| Net Income | -$7.31M↓ | -$3.50M↓ | -$3.02M↑ | -$3.20M↓ | -$2.66M |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treat...